Allogene Therapeutics (ALLO) Profit After Tax: 2019-2025
Historic Profit After Tax for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to -$41.4 million.
- Allogene Therapeutics' Profit After Tax rose 37.55% to -$41.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$209.6 million, marking a year-over-year increase of 88.09%. This contributed to the annual value of -$257.6 million for FY2024, which is 21.29% up from last year.
- As of Q3 2025, Allogene Therapeutics' Profit After Tax stood at -$41.4 million, which was up 18.73% from -$50.9 million recorded in Q2 2025.
- Allogene Therapeutics' Profit After Tax's 5-year high stood at -$33.0 million during Q1 2021, with a 5-year trough of -$1.6 billion in Q4 2023.
- Moreover, its 3-year median value for Profit After Tax was -$65.0 million (2024), whereas its average is -$201.0 million.
- Per our database at Business Quant, Allogene Therapeutics' Profit After Tax tumbled by 138.09% in 2022 and then surged by 96.32% in 2024.
- Over the past 5 years, Allogene Therapeutics' Profit After Tax (Quarterly) stood at -$903.3 million in 2021, then plummeted by 36.72% to -$1.2 billion in 2022, then decreased by 26.49% to -$1.6 billion in 2023, then soared by 96.32% to -$57.5 million in 2024, then skyrocketed by 37.55% to -$41.4 million in 2025.
- Its Profit After Tax stands at -$41.4 million for Q3 2025, versus -$50.9 million for Q2 2025 and -$59.7 million for Q1 2025.